Stay updated on Dolutegravir vs Lopinavir/Ritonavir in Second-line Clinical Trial

Sign up to get notified when there's something new on the Dolutegravir vs Lopinavir/Ritonavir in Second-line Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Dolutegravir vs Lopinavir/Ritonavir in Second-line Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the dolutegravir versus lopinavir/ritonavir study is available again, including detailed study results, participant criteria, and data-sharing and study documents.
    Difference
    90%
    Check dated 2026-11-09T13:58:24.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T16:13:31.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    A site-wide NIH notice about terminology changes appears above the ClinicalTrials.gov error page.
    Difference
    1%
    Check dated 2026-10-26T16:08:32.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov page.
    Difference
    0.2%
    Check dated 2026-10-19T16:51:41.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The footer revision number changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-12T17:08:20.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, rendering the study record inaccessible. The usual study details and documents are no longer visible on the page.
    Difference
    20%
    Check dated 2026-09-21T20:44:29.000Z thumbnail image

Stay in the know with updates to Dolutegravir vs Lopinavir/Ritonavir in Second-line Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Dolutegravir vs Lopinavir/Ritonavir in Second-line Clinical Trial page.